Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
Each line starts at 100 so growth is directly comparable
| Metric | MRNA | TMO |
|---|---|---|
| Price | $185.08 | $672.85 |
| Change today | ▲ 1.63% | ▲ 1.13% |
| Market cap | $73.89B | $248.78B |
| Return, 3 months | +206.3% | +36.7% |
| Return, year to date | +527.6% | +16.4% |
| Return, 1 year | +615.1% | +44.2% |
| P/E (TTM) | -23.2 | 36.2 |
| P/B | 10.9 | 4.7 |
| P/E percentile vs own 5y | 1st | 63rd |
| Dividend yield | – | 0.27% |
| Revenue growth (YoY, latest qtr) | +4.4% | +10.5% |
| Net profit growth (YoY) | +5.2% | +7.6% |
| Gross margin | 22.8% | 40.8% |
| Operating margin | -150.2% | 18.3% |
| Net margin | -142.6% | 15.0% |
| Return on equity | -39.0% | 13.5% |
| Analyst target vs. price | -38.7% | -4.9% |
| Analyst buy share | 23% | 83% |
| RSI (14) | 73 | 69 |
| 30-day volatility | 315.6% | 24.7% |
| Max drawdown, 1 year | -34.2% | -31.4% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Hold | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.